| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/09/2009 | US20090176881 Unsaturated Alkyl Esters of 5-Aminolevulinic Acid, their Preparation and their Use |
| 07/09/2009 | US20090176874 Tnp-470 polymer conjugates and use thereof |
| 07/09/2009 | US20090176853 Adamantane derivatives |
| 07/09/2009 | US20090176852 Temozolomide FDA Orange book listed patent; water soluble, and storage stable formulation; L-threonine as dissolution enhancer |
| 07/09/2009 | US20090176841 Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility |
| 07/09/2009 | US20090176837 Compounds with activity at retinoic acid receptors |
| 07/09/2009 | US20090176821 Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4-Amino-1H-Imidazo[4,5-C] Quinolin-1-YL)Butyl]Methanesulfonamides and Methods |
| 07/09/2009 | US20090176820 Polymorphic forms and process |
| 07/09/2009 | US20090176819 39-Desmethoxy-39-Methyl Derivatives of Rapamycin |
| 07/09/2009 | US20090176809 Raf inhibitor compounds and methods |
| 07/09/2009 | US20090176807 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 07/09/2009 | US20090176806 protein kinase C or glycogen synthase kinase-3-beta inhibitors such as 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-1H-pyrrole-2,5-dione, used for treating cardiovascular, skin, nervous system disorders and immunological disorders, diabetes, inflammatory diseases and cancer |
| 07/09/2009 | US20090176801 Novel lapachone compounds and methods of use thereof |
| 07/09/2009 | US20090176797 Pharmaceutical composition for treating esophageal cancer |
| 07/09/2009 | US20090176782 Inhibitors of tace |
| 07/09/2009 | US20090176781 Acetylenic Heteroaryl Compounds |
| 07/09/2009 | US20090176780 Nitrogenous heterocyclic compounds |
| 07/09/2009 | US20090176779 Pyrazolo[4,3-d]thiazole derivatives, and preparation and therapeutic application thereof |
| 07/09/2009 | US20090176765 Pyridinone and Pyridazinone Derivatives as Inhibitors of Poly (Adp-Ribose) Polymerase (Parp) |
| 07/09/2009 | US20090176764 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 07/09/2009 | US20090176763 Azaindoles useful as inhibitors of JAK and other protein kinases |
| 07/09/2009 | US20090176759 Leukemic stem cell ablation |
| 07/09/2009 | US20090176753 Betulinol derivatives as anti-cancer agents |
| 07/09/2009 | US20090176752 Use of potent antiandrogen compounds with lower androgenic activities, such as 3 beta -acetoxyandrost-1,5-diene-17-ethylene ketal (ADEK) and 3 beta -hydroxyandrost-1,5-diene-17-ethylene ketal; androgen-independent prostate cancer |
| 07/09/2009 | US20090176747 Tetracycline compounds and methods of treatment |
| 07/09/2009 | US20090176746 4'-{N'-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-3'-hydroxybiphenyl-4-carboxylic acid; Promotes thrombopoiesis and megakaryocytopoiesis |
| 07/09/2009 | US20090176745 Triarylmethane analogs and their use in treating cancers |
| 07/09/2009 | US20090176731 Combination therapy of cancer with azd2171 and gemcitabine |
| 07/09/2009 | US20090176727 Double-stranded rna structures and constructs, and methods for generating and using the same |
| 07/09/2009 | US20090176726 Methods for treating mitf-related disorders |
| 07/09/2009 | US20090176724 Methods and Compositions for the Diagnosis, Prognosis and Treatment of Cancer |
| 07/09/2009 | US20090176716 Inhibitors of cancer cell, t-cell and keratinocyte proliferation |
| 07/09/2009 | US20090176707 Human signal peptide-containing proteins |
| 07/09/2009 | US20090176706 Materials and methods for treatment of inflammatory and cell proliferation disorders |
| 07/09/2009 | US20090176705 Modular platform for targeted therapeutic delivery |
| 07/09/2009 | US20090176695 Reagents and Methods for Smooth Muscle Therapies |
| 07/09/2009 | US20090176694 Reagents and Methods for Smooth Muscle Therapies |
| 07/09/2009 | US20090176691 Pharmaceutical Compositions Containing at Least One Protein Active Ingredient Protected From Digestive Enzymes |
| 07/09/2009 | US20090175970 Stabilized Plant Extract and Its Therapeutic Use |
| 07/09/2009 | US20090175967 Methods for treatment of intestinal carcinogenesis with rice bran |
| 07/09/2009 | US20090175951 Nanoparticulate compositions of immunosuppressive agents |
| 07/09/2009 | US20090175947 Pharmaceutical composition for injectional particularly targeted local administration |
| 07/09/2009 | US20090175893 Albumin-Fused Anti-Angiogenesis Peptides |
| 07/09/2009 | US20090175888 Methods of treating cancer with an antibody-drug conjugate |
| 07/09/2009 | US20090175886 Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| 07/09/2009 | US20090175885 Method of controlling insect pests in cotton |
| 07/09/2009 | US20090175877 Methods of inhibiting metastasis |
| 07/09/2009 | US20090175873 Inhibiting tumor cell invasion, metastasis and angiogenesis |
| 07/09/2009 | US20090175871 Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors |
| 07/09/2009 | US20090175869 Pulsatile Dosing of Gossypol for Treatment of Disease |
| 07/09/2009 | US20090175865 using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells |
| 07/09/2009 | US20090175862 Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| 07/09/2009 | US20090175860 Compositions and Methods of Use for Antibodies of c-Met |
| 07/09/2009 | US20090175858 Crystalline EGFR - matuzumab complex and matuzumab mimetics obtained thereof |
| 07/09/2009 | US20090175856 Anti-Proliferative Combination Therapy Using Certain Platinum-Based Chemotherapeutic Agents and EGFR Inhibitors or Pyrimidine Analogues |
| 07/09/2009 | US20090175852 Imidazopyrazines as protein kinase inhibitors |
| 07/09/2009 | US20090175844 Method of diagnosing bladder cancer |
| 07/09/2009 | US20090175836 Prelamin a pre peptide as a universal stem cell differentiation signal |
| 07/09/2009 | US20090175830 Oncolytic adenovirus armed with therapeutic genes |
| 07/09/2009 | US20090175825 Interferon alpha and antisense k-ras rna combination gene therapy |
| 07/09/2009 | US20090175801 Cns-tumor treatment method and composition |
| 07/09/2009 | US20090175796 Antibodies and related molecules that bind to 24p4c12 proteins |
| 07/09/2009 | US20090175794 Inhibitors of carbonic anhydrase ix |
| 07/09/2009 | US20090175791 Anti-VEGF Antibody Compositions and Methods |
| 07/09/2009 | US20090175786 Gastrin Releasing Peptide Compounds |
| 07/09/2009 | CA2712358A1 Benzofuropyrimidinones as protein kinase inhibitors |
| 07/09/2009 | CA2711141A1 Hydroxy-bisphosphonic acid derivatives as vector for targeting bone tissue |
| 07/09/2009 | CA2710977A1 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs |
| 07/09/2009 | CA2710974A1 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs |
| 07/09/2009 | CA2710970A1 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs |
| 07/09/2009 | CA2710954A1 (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs |
| 07/09/2009 | CA2710928A1 Parvovirus cancer therapy and combination with chemotherapy |
| 07/09/2009 | CA2710920A1 Anti-proliferative compounds and their use |
| 07/09/2009 | CA2710740A1 Antitumor agent |
| 07/09/2009 | CA2710713A1 Silencing of polo-like kinase expression using interfering rna |
| 07/09/2009 | CA2710379A1 Compositions containing sesamin-class compound(s) and quercetin glycoside(s) |
| 07/09/2009 | CA2710194A1 Inhibitors of p13 kinase |
| 07/09/2009 | CA2710092A1 Pyridazinone derivatives |
| 07/09/2009 | CA2710082A1 Methods for using and identifying modulators of delta-like 4 |
| 07/09/2009 | CA2709710A1 Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors |
| 07/09/2009 | CA2709399A1 Anti-hedgehog antibodies |
| 07/09/2009 | CA2709227A1 Stable elsamitrucin salt formulations |
| 07/09/2009 | CA2709202A1 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| 07/09/2009 | CA2708648A1 Fdf03 antibodies and uses thereof |
| 07/09/2009 | CA2704125A1 8-anilin0imidaz0pyridines and their use as anti-cancer and/or anti-inflammatory agents |
| 07/08/2009 | EP2077326A1 Novel nucleic acid |
| 07/08/2009 | EP2077293A1 Block copolymer for drug complex and pharmaceutical composition |
| 07/08/2009 | EP2077271A1 Macrolide derivative |
| 07/08/2009 | EP2076542A1 Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers |
| 07/08/2009 | EP2076539A2 Antibody molecules which bind il-17a and il-17f |
| 07/08/2009 | EP2076538A2 Materials and methods for improved immunoglycoproteins |
| 07/08/2009 | EP2076516A2 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| 07/08/2009 | EP2076507A2 Imatinib base, and imatinib mesylate and processes for preparation thereof |
| 07/08/2009 | EP2076289A2 Methods for treating cancer resistant to erbb therapeutics |
| 07/08/2009 | EP2076263A2 Discontinuous methods of treating cancer |
| 07/08/2009 | EP2076260A1 N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| 07/08/2009 | EP2076259A2 Methods of treating ovarian cancer |
| 07/08/2009 | EP2076254A2 Combination with bis(thiohydrazide amides) for treating cancer |
| 07/08/2009 | EP2076243A1 Liquid formulation of g-csf |
| 07/08/2009 | EP2076132A1 P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one and methods for preparation |